Posted by Michael Wonder on 06 Oct 2021
US FDA grants fast track designation for JR-171 for the treatment of mucopolysaccaridosis type I
5 October 2021 - JCR Pharmaceuticals announced today that the US FDA has granted fast track designation for the investigational drug JR-171 for the treatment of mucopolysaccaridosis I (Hurler, Hurler-Scheie and Scheie syndrome).
JR-171 is a blood brain barrier penetrating form recombinant α-L-iduronidase that was developed using JCR’s proprietary J-Brain Cargo blood brain barrier technology.
